* A new sodium–glucose cotransporter 2 inhibitor, dapagliflozin (Farxiga), has been approved to control type 2 diabetes.
* Hypotension is possible with dapagliflozin use, and the drug can alter renal function. Hypovolemia should be corrected prior to the start of treatment. Kidney function and glucose levels should be assessed throughout therapy.
* The most common adverse effects are genital yeast infections, nasopharyngitis, and urinary tract infections.